Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegbelfermin PK/Safety in Healthy Overweight/Obese Chinese and Korean Participants
NCT04649710Phase 1Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of pegbelfermin in Nonalcoholic steatohepatitis (NASH) (4 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Time of maximum observed plasma concentration and 1 more. Planned start Jun 2021; status: withdrawn.
02
Drugs
pegbelfermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04649710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649710.